Esculentin-1a-derived peptides promote clearance of pseudomonas aeruginosa internalized in bronchial cells of cystic fibrosis patients and lung cell migration: Biochemical properties and a plausible mode of action

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 12, 2016, Pages 7252-7262

  Cappiello, Floriana ^a   Di Grazia, Antonio ^a   Segev Zarko, Li Av ^b   Scali, Silvia ^c   Ferrera, Loretta ^d   Galietta, Luis ^d   Pini, Alessandro ^c   Shai, Yechiel ^b   Di, Y Peter ^e   Mangoni, Maria Luisa ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c UNIVERSITY OF SIENA   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ELASTASE; ESCULENTIN 1A DERIVED PEPTIDE; ESCULENTIN(1-21); ESCULENTIN(1-21) 1C; MUTANT PROTEIN; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; AMPHIBIAN PROTEIN; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; ESCULENTIN PROTEIN, RANA ESCULENTA; LIPOPOLYSACCHARIDE;

AIRWAY EPITHELIAL CELL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; BIOCHEMICAL ANALYSIS; BRONCHUS; CELL MIGRATION; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYSTIC FIBROSIS; DIASTEREOISOMER; DRUG MECHANISM; EPITHELIZATION; HUMAN; HUMAN CELL; INTERNALIZATION; LUNG ALVEOLUS CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; CELL CULTURE; CELL MOTION; CHEMISTRY; DRUG EFFECTS; EPITHELIUM CELL; GENETICS; METABOLISM; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; RESPIRATORY MUCOSA;

AMPHIBIAN PROTEINS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL MOVEMENT; CELLS, CULTURED; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CELLS; HUMANS; LIPOPOLYSACCHARIDES; MICROSCOPY, CONFOCAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY MUCOSA;

EID: 84996598117     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00904-16     Document Type: Article

References (69)

1. Hancock RE, Speert DP 2000. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat 3:247-255. http://dx.doi.org/10.1054/drup.2000.0152.
2. Mah TF, Pitts B, Pellock B., Walker GC, Stewart PS, O'Toole GA. 2003. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426:306-310. http://dx.doi.org/10.1038/nature02122.
3. Drenkard E, Ausubel FM 2002. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416:740-743. http://dx.doi.org/10.1038/416740a.
4. Costerton JW, Stewart PS, Greenberg EP 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. http://dx.doi.org/10.1126/science.284.5418.1318.
5. Stewart PS, Costerton JW 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138. http://dx.doi.org/10.1016/S0140-6736(01)05321-1.
6. Mangoni ML, Luca V, McDermott AM 2015. Fighting microbial infections: a lesson from amphibian skin-derived esculentin-1 peptides. Peptides 71:286-295. http://dx.doi.org/10.1016/j.peptides.2015.04.018.
7. Larrosa M, Truchado P, Espin J.C., Tomas-Barberan FA, Allende A, Garcia-Conesa MT. 2012. Evaluation of Pseudomonas aeruginosa (PAO1) adhesion to human alveolar epithelial cells A549 using SYTO 9 dye. Mol Cell Probes 26:121-126. http://dx.doi.org/10.1016/j.mcp.2012.03.001.
8. Millar FA, Simmonds NJ, Hodson ME 2009. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. J Cyst Fibros 8:386-391. http://dx.doi.org/10.1016/j.jcf.2009.08.003.
9. Kerem B, Rommens JM, Buchanan J.A., Markiewicz D., Cox TK, Chakravarti A, Buchwald M, Tsui LC 1989. Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073-1080. http://dx.doi.org/10.1126/science.2570460.
10. Welsh M, Tsui L, Boat T., Beaudet A. 1995. Cystic fibrosis, p 3799-3863. In Scriver CR, Beaudet AL, Sly WS, Valle D (ed), The metabolic bases of inherited disease, 7th ed. McGraw-Hill, New York, NY.
11. Evans CM, Koo JS 2009. Airway mucus: the good, the bad, the sticky. Pharmacol Ther 121:332-348. http://dx.doi.org/10.1016/j.pharmthera.2008.11.001.
12. Chace KV, Flux M, Sachdev GP 1985. Comparison of physicochemical properties of purified mucus glycoproteins isolated from respiratory secretions of cystic fibrosis and asthmatic patients. Biochemistry 24:7334-7341. http://dx.doi.org/10.1021/bi00346a047.
13. Moreau-Marquis S., Stanton BA, O'Toole GA. 2008. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm Pharmacol Ther 21:595-599. http://dx.doi.org/10.1016/j.pupt.2007.12.001.
14. Bals R, Weiner DJ, Wilson JM 1999. The innate immune system in cystic fibrosis lung disease. J Clin Investig 103:303-307. http://dx.doi.org/10.1172/JCI6277.
15. Chiappini E, Taccetti G, de Martino M. 2014. Bacterial lung infections in cystic fibrosis patients: an update. Pediatr Infect Dis J 33:653-654. http://dx.doi.org/10.1097/INF.0000000000000347.
16. Hirakata Y, Izumikawa K, Yamaguchi T., Igimi S, Furuya N, Maesaki S., Tomono K, Yamada Y, Kohno S., Yamaguchi K, Kamihira S. 1998. Adherence to and penetration of human intestinal Caco-2 epithelial cell monolayers by Pseudomonas aeruginosa. Infect Immun 66:1748-1751.
17. Chi E, Mehl T, Nunn D., Lory S. 1991. Interaction of Pseudomonas aeruginosa with A549 pneumocyte cells. Infect Immun 59:822-828.
18. Lyczak JB, Cannon CL, Pier GB 2000. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2:1051-1060. http://dx.doi.org/10.1016/S1286-4579(00)01259-4.
19. Hart CA, Winstanley C. 2002. Persistent and aggressive bacteria in the lungs of cystic fibrosis children. Br Med Bull 61:81-96. http://dx.doi.org/10.1093/bmb/61.1.81.
20. Pier GB, Grout M, Zaidi TS 1997. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci U S A 94:12088-12093. http://dx.doi.org/10.1073/pnas.94.22.12088.
21. Pier GB, Grout M, Zaidi T.S., Olsen JC, Johnson LG, Yankaskas JR, Goldberg JB 1996. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 271:64-67. http://dx.doi.org/10.1126/science.271.5245.64.
22. Esen M, Grassme H, Riethmuller J., Riehle A, Fassbender K, Gulbins E. 2001. Invasion of human epithelial cells by Pseudomonas aeruginosa involves src-like tyrosine kinases p60Src and p59Fyn. Infect Immun 69:281-287. http://dx.doi.org/10.1128/IAI.69.1.281-287.2001.
23. Darling KE, Evans TJ 2003. Effects of nitric oxide on Pseudomonas aeruginosa infection of epithelial cells from a human respiratory cell line derived from a patient with cystic fibrosis. Infect Immun 71:2341-2349. http://dx.doi.org/10.1128/IAI.71.5.2341-2349.2003.
24. Darling KE, Dewar A, Evans TJ 2004. Role of the cystic fibrosis transmembrane conductance regulator in internalization of Pseudomonas aeruginosa by polarized respiratory epithelial cells. Cell Microbiol 6:521-533. http://dx.doi.org/10.1111/j.1462-5822.2004.00380.x.
25. Ko YH, Delannoy M, Pedersen PL 1997. Cystic fibrosis, lung infections, and a human tracheal antimicrobial peptide (hTAP). FEBS Lett 405:200-208. http://dx.doi.org/10.1016/S0014-5793(97)00189-0.
26. Ben Haj Khalifa A, Moissenet D, Vu Thien H, Khedher M. 2011. Virulence factors in Pseudomonas aeruginosa: mechanisms and modes of regulation. Ann Biol Clin 69:393-403.
27. Sana TG, Baumann C, Merdes A., Soscia C, Rattei T, Hachani A., Jones C, Bennett KL, Filloux A, Superti-Furga G, Voulhoux R., Bleves S. 2015. Internalization of Pseudomonas aeruginosa strain PAO1 into epithelial cells is promoted by interaction of a T6SS effector with the microtubule network. mBio 6:e00712. http://dx.doi.org/10.1128/mBio.00712-15.
28. Brinch KS, Frimodt-Moller N, Hoiby N., Kristensen HH. 2009. Influence of antidrug antibodies on plectasin efficacy and pharmacokinetics. Antimicrob Agents Chemother 53:4794-4800. http://dx.doi.org/10.1128/AAC.00440-09.
29. Haney EF, Hancock RB 2013. Peptide design for antimicrobial and immunomodulatory applications. Biopolymers 100:572-583. http://dx.doi.org/10.1002/bip.22250.
30. Cruz J, Ortiz C, Guzman F., Fernandez-Lafuente R, Torres R. 2014. Antimicrobial peptides: promising compounds against pathogenic microorganisms. Curr Med Chem 21:2299-2321. http://dx.doi.org/10.2174/0929867321666140217110155.
31. Mansour SC, Pena OM, Hancock RE 2014. Host defense peptides: front-line immunomodulators. Trends Immunol 35:443-450. http://dx.doi.org/10.1016/j.it.2014.07.004.
32. Epand RM, Vogel HJ 1999. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1462:11-28. http://dx.doi.org/10.1016/S0005-2736(99)00198-4.
33. Shai Y. 2002. Mode of action of membrane active antimicrobial peptides. Biopolymers 66:236-248. http://dx.doi.org/10.1002/bip.10260.
34. Islas-Rodriguez A.E., Marcellini L, Orioni B., Barra D, Stella L, Mangoni ML 2009. Esculentin 1-21: a linear antimicrobial peptide from frog skin with inhibitory effect on bovine mastitis-causing bacteria. J Pept Sci 15: 607-614. http://dx.doi.org/10.1002/psc.1148.
35. Luca V, Stringaro A, Colone M., Pini A, Mangoni ML. 2013. Esculentin(1-21), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa. Cell Mol Life Sci 70:2773-2786. http://dx.doi.org/10.1007/s00018-013-1291-7.
36. Di Grazia A., Cappiello F, Cohen H., Casciaro B, Luca V, Pini A., Di YP, Shai Y, Mangoni ML. 2015. D-Amino acids incorporation in the frog skin-derived peptide esculentin-1a(1-21)NH is beneficial for its multiple functions. Amino Acids 47:2505-2519. http://dx.doi.org/10.1007/s00726-015-2041-y.
37. Bebok Z, Collawn JF, Wakefield J, Parker W., Li Y, Varga K, Sorscher E.J., Clancy JP. 2005. Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o-airway epithelial monolayers. J Physiol 569:601-615. http://dx.doi.org/10.1113/jphysiol.2005.096669.
38. Lore NI, Cigana C, De Fino I, Riva C, Juhas M., Schwager S, Eberl L, Bragonzi A. 2012. Cystic fibrosis-niche adaptation of Pseudomonas aeruginosa reduces virulence in multiple infection hosts. PLoS One 7:e35648. http://dx.doi.org/10.1371/journal.pone.0035648.
39. Bragonzi A, Paroni M, Nonis A., Cramer N, Montanari S, Rejman J., Di Serio C, Doring G, Tummler B. 2009. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am J Respir Crit Care Med 180:138-145. http://dx.doi.org/10.1164/rccm.200812-1943OC.
40. Grieco P, Carotenuto A, Auriemma L., Limatola A, Di Maro S, Merlino F, Mangoni M.L., Luca V., Di Grazia A, Gatti S, Campiglia P., Gomez-Monterrey I, Novellino E, Catania A. 2013. Novel alpha-MSH peptide analogues with broad spectrum antimicrobial activity. PLoS One 8:e61614. http://dx.doi.org/10.1371/journal.pone.0061614.
41. Di Grazia A., Cappiello F, Imanishi A., Mastrofrancesco A, Picardo M, Paus R., Mangoni ML. 2015. The frog skin-derived antimicrobial peptide esculentin-1a(1-21)NH2 promotes the migration of human HaCaT keratinocytes in an EGF receptor-dependent manner: a novel promoter of human skin wound healing? PLoS One 10:e0128663. http://dx.doi.org/10.1371/journal.pone.0128663.
42. Kim S, Beyer BA, Lewis C, Nadel JA 2013. Normal CFTR inhibits epidermal growth factor receptor-dependent pro-inflammatory chemokine production in human airway epithelial cells. PLoS One 8:e72981. http://dx.doi.org/10.1371/journal.pone.0072981.
43. Renier M, Tamanini A, Nicolis E., Rolfini R, Imler JL, Pavirani A, Cabrini G. 1995. Use of a membrane potential-sensitive probe to assess biological expression of the cystic fibrosis transmembrane conductance regulator. Hum Gene Ther 6:1275-1283. http://dx.doi.org/10.1089/hum.1995.6.10-1275.
44. Hamai H, Keyserman F, Quittell L.M., Worgall TS. 2009. Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling. J Lipid Res 50:1101-1108. http://dx.doi.org/10.1194/jlr.M800427-JLR200.
45. Trinh NT, Bardou O, Prive A., Maille E, Adam D, Lingee S., Ferraro P, Desrosiers MY, Coraux C, Brochiero E. 2012. Improvement of defective cystic fibrosis airway epithelial wound repair after CFTR rescue. Eur Respir J 40:1390-1400. http://dx.doi.org/10.1183/09031936.00221711.
46. Schiller KR, Maniak PJ, O'Grady SM. 2010. Cystic fibrosis transmembrane conductance regulatorisinvolvedinairway epithelial wound repair. Am J Physiol Cell Physiol 299:C912-C921. http://dx.doi.org/10.1152/ajpcell.00215.2010.
47. Rietschel ET, Kirikae T, Schade F.U., Mamat U., Schmidt G, Loppnow H, Ulmer A.J., Zahringer U., Seydel U, Di Padova F, Schreier M, Brade H. 1994. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 8:217-225.
48. Koff JL, Shao MX, Kim S, Ueki I.F., Nadel JA. 2006. Pseudomonas lipopolysaccharide accelerates wound repair via activation of a novel epithelial cell signaling cascade. J Immunol 177:8693-8700. http://dx.doi.org/10.4049/jimmunol.177.12.8693.
49. Bucki R, Byfield FJ, Janmey PA 2007. Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. Eur Respir J 29:624-632. http://dx.doi.org/10.1183/09031936.00080806.
50. Byfield FJ, Kowalski M, Cruz K., Leszczynska K, Namiot A, Savage P.B., Bucki R., Janmey PA. 2011. Cathelicidin LL-37 increases lung epithelial cell stiffness, decreases transepithelial permeability, and prevents epithelial invasion byPseudomonas aeruginosa. J Immunol 187:6402-6409. http://dx.doi.org/10.4049/jimmunol.1102185.
51. Burgel PR, Nadel JA 2004. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. Thorax 59:992-996. http://dx.doi.org/10.1136/thx.2003.018879.
52. Gan HK, Walker F, Burgess A.W., Rigopoulos A., Scott AM, Johns TG. 2007. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. J Biol Chem 282:2840-2850.
53. Midura-Nowaczek K., Markowska A. 2014. Antimicrobial peptides and their analogs: searching for new potential therapeutics. Perspect Medicin Chem 6:73-80.
54. Nguyen LT, Chau JK, Perry N.A., de Boer L, Zaat SA, Vogel HJ 2010. Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS One 5:e12684. http://dx.doi.org/10.1371/journal.pone.0012684.
55. Liu H, Lazarus SC, Caughey G.H., Fahy JV. 1999. Neutrophil elastase and elastase-rich cystic fibrosis sputum degranulate human eosinophils in vitro. Am J Physiol 276:L28-L34.
56. Lovewell RR, Patankar YR, Berwin B. 2014. Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 306:L591-L603. http://dx.doi.org/10.1152/ajplung.00335.2013.
57. Mariencheck WI, Alcorn JF, Palmer S.M., Wright JR. 2003. Pseudomonas aeruginosa elastase degrades surfactant proteins A and D. Am J Respir Cell Mol Biol 28:528-537. http://dx.doi.org/10.1165/rcmb.2002-0141OC.
58. Morris CJ, Beck K, Fox M.A., Ulaeto D., Clark GC, Gumbleton M. 2012. Pegylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway delivery. Antimicrob Agents Chemother 56:3298-3308. http://dx.doi.org/10.1128/AAC.06335-11.
59. Brayton JJ, Yang Q, Nakkula R.J., Walters JD. 2002. An in vitro model of ciprofloxacin and minocycline transport by oral epithelial cells. J Periodontol 73:1267-1272. http://dx.doi.org/10.1902/jop.2002.73.11.1267.
60. Bonventre PF, Hayes R, Imhoff J. 1967. Autoradiographic evidence for the impermeability of mouse peritoneal macrophages to tritiated streptomycin. J Bacteriol 93:445-450.
61. Chadwick PR, Mellersh AR 1987. The use of a tissue culture model to assess the penetration of antibiotics into epithelial cells. J Antimicrob Chemother 19:211-220. http://dx.doi.org/10.1093/jac/19.2.211.
62. Ilgin S, Can OD, Atli O, Ucel U.I., Sener E., Guven I. 2015. Ciprofloxacininduced neurotoxicity: evaluation of possible underlying mechanisms. Toxicol Mech Methods 25:374-381. http://dx.doi.org/10.3109/15376516.2015.1026008.
63. Yayan J, Ghebremedhin B, Rasche K. 2015. No outbreak of vancomycin and linezolid resistance in Staphylococcal pneumonia over a 10-year period. PLoS One 10:e0138895. http://dx.doi.org/10.1371/journal.pone.0138895.
64. Drin G, Cottin S, Blanc E., Rees AR, Temsamani J. 2003. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 278:31192-31201. http://dx.doi.org/10.1074/jbc.M303938200.
65. Lau YE, Rozek A, Scott M.G., Goosney DL, Davidson DJ, Hancock RE. 2005. Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect Immun 73:583-591. http://dx.doi.org/10.1128/IAI.73.1.583-591.2005.
66. Peschon JJ, Slack JL, Reddy P, Stocking K.L., Sunnarborg SW, Lee DC, Russell WE, Castner B.J., Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky C.J., Wolfson MF, Rauch CT, Cerretti DP, Paxton R.J., March CJ, Black RA. 1998. An essential role for ectodomain shedding in mammalian development. Science 282:1281-1284. http://dx.doi.org/10.1126/science.282.5392.1281.
67. Shao MX, Ueki IF, Nadel JA 2003. Tumor necrosis factor alphaconverting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells. Proc Natl Acad Sci U S A 100:11618-11623. http://dx.doi.org/10.1073/pnas.1534804100.
68. Park BS, Lee JO 2013. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med 45:e66. http://dx.doi.org/10.1038/emm.2013.97.
69. Santos NC, Silva AC, Castanho M.A., Martins-Silva J, Saldanha C. 2003. Evaluation of lipopolysaccharide aggregation by light scattering spectroscopy. Chembiochem 4:96-100. http://dx.doi.org/10.1002/cbic.200390020.